MIR199A1 (MicroRNA 199a-1)

miRNAs are crucial in BC treatment with PARP inhibitors. Further clinical studies are needed to validate their roles and develop miRNA-based strategies to overcome PARP inhibitor resistance.

Moreover, miR-199a-3p overexpression and CD151 silencing upregulated MMP2 expression in TECs. Taken together, these results suggest that miR-199a-3p contributes to the proangiogenic phenotype in TECs by suppressing CD151 expression.Key words: miR-199a-3p, tumor endothelial cells, CD151, angiogenesis, cell migration and invasion.

From a therapeutic point of view, miR-199a-3p replacement synergized with palbociclib and overcame sorafenib resistance. This review highlights the importance of the TG221 transgenic mouse as a powerful model for studying miRNA-driven hepatocarcinogenesis and enables preclinical evaluation of RNA-based chemopreventive and therapeutic approaches. Metformin, miRNA inhibition, miRNA replacement and miRNA-guided viral therapies emerge as promising approaches for advancing precision prevention and treatment strategies in HCC.

LncRNA NPSR1-AS1 targets miR-199a-3p and affects the progression of BCa. Moreover, it can serve as a biomarker for BCa.

Background: HER2-positive breast cancer patients receiving chemotherapy and targeted therapy (including anthracyclines and trastuzumab) face an elevated risk of cardiotoxicity, which can lead to long-term cardiovascular complications... Circulating miRNAs show promise as biomarkers for predicting cardiotoxicity in breast cancer patients. Machine learning approaches may enhance miRNA-based risk stratification, enabling personalized monitoring and early cardioprotective interventions.

In the training and validation sets, the area under the curve of the 4-miRNA panel was 0.909 and 0.942, respectively. These findings suggest that the serum glycosylated exosomal 4-miRNA panel developed using the GlyExo-Capture approach may serve as a promising strategy for liquid biopsy-based early detection of LUAD.

PDHA1, OGG1, and OPA1 were identified as potential prognostic markers for pediatric AML, providing valuable insights for the development of targeted therapeutic strategies. However, further validation in larger and more diverse clinical cohorts is still required to confirm its clinical applicability.

These findings underscore the critical roles of miR-125b-5p and miR-100-5p in PM-associated lung cancer progression and their potential as biomarkers and therapeutic targets. This study highlights distinct mechanisms of lung carcinogenesis in smokers and non-smokers, providing a foundation for targeted interventions in PM-associated lung cancer.

Collectively, these findings demonstrate that miR‑199a‑3p suppresses NSCLC progression by targeting FTO, promoting m6A methylation‑dependent downregulation of MZF1, and consequently decreasing CLDND1 expression. Thus, the miR‑199a‑3p/FTO/MZF1/CLDND1 axis may serve as a promising therapeutic target in NSCLC.

Given the strong link between chronic inflammation and LC aggressiveness, this study positions TQ as a promising therapeutic candidate, especially for inflammation-mediated lung cancer progression. Its dual ability to modulate miRNA and key signaling cascades makes it a compelling option for future LC treatment strategies.

Our results indicate that miR-199a-3p, miR-199a-5p, and miR-148a-5p are involved in key metastatic processes, suggesting their relevance as potential biomarkers and/or therapeutic targets for thyroid tumors. Further in vivo validation and clinical studies are required to explore their translational applications.

This miRNA panel outperformed the World Health Organization -endorsed Xpert MTB/RIF assay, effectively identifying early-stage PTB cases without cavity formation. These findings underscore the potential of miRNA-based diagnostics as a non-invasive and highly accurate tool for differentiating PTB from LC in patients with comparable imaging presentations, addressing a critical gap in pulmonary disease management.